Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti.

Zika virus (ZIKV), an emerging arbovirus belonging to the genus Flavivirus, is transmitted by Aedes mosquitoes. ZIKV infection can cause microcephaly of newborn babies and Guillain-Barré syndrome in adults. Because no licensed vaccine or specific antiviral treatment is available for ZIKV infection,...

Full description

Bibliographic Details
Main Authors: Shengzhang Dong, Seokyoung Kang, George Dimopoulos
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-08-01
Series:PLoS Neglected Tropical Diseases
Online Access:https://doi.org/10.1371/journal.pntd.0007681
_version_ 1818729818516094976
author Shengzhang Dong
Seokyoung Kang
George Dimopoulos
author_facet Shengzhang Dong
Seokyoung Kang
George Dimopoulos
author_sort Shengzhang Dong
collection DOAJ
description Zika virus (ZIKV), an emerging arbovirus belonging to the genus Flavivirus, is transmitted by Aedes mosquitoes. ZIKV infection can cause microcephaly of newborn babies and Guillain-Barré syndrome in adults. Because no licensed vaccine or specific antiviral treatment is available for ZIKV infection, the most commonly used approach to control the spread of ZIKV is suppression of the mosquito vector population. A novel proposed strategy to block arthropod virus (arbovirus) transmission is based on the chemical inhibition of virus infection in mosquitoes. However, only a few drugs and compounds have been tested with such properties. Here we present a comprehensive screen of 55 FDA-approved anti-flaviviral drugs for potential anti-ZIKV and mosquitocidal activity. Four drugs (auranofin, actinomycin D (Act-D), bortezomib and gemcitabine) were toxic to C6/36 cells, and two drugs (5-fluorouracil and mycophenolic acid (MPA)) significantly reduced ZIKV production in C6/36 cells at 2 μM and 0.5 μM, respectively. Three drugs (Act-D, cyclosporin A, ivermectin) exhibited a strong adulticidal activity, and six drugs (U18666A, retinoic acid p-hydroxyanilide (4-HPR), clotrimazole, bortezomib, MPA, imatinib mesylate) significantly suppressed ZIKV infection in mosquito midguts. Some of these FDA-approved drugs may have potential for use for the development of ZIKV transmission-blocking strategies.
first_indexed 2024-12-17T22:51:56Z
format Article
id doaj.art-df892d7a6c4f46e2959039e187f8cf0e
institution Directory Open Access Journal
issn 1935-2727
1935-2735
language English
last_indexed 2024-12-17T22:51:56Z
publishDate 2019-08-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS Neglected Tropical Diseases
spelling doaj.art-df892d7a6c4f46e2959039e187f8cf0e2022-12-21T21:29:38ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352019-08-01138e000768110.1371/journal.pntd.0007681Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti.Shengzhang DongSeokyoung KangGeorge DimopoulosZika virus (ZIKV), an emerging arbovirus belonging to the genus Flavivirus, is transmitted by Aedes mosquitoes. ZIKV infection can cause microcephaly of newborn babies and Guillain-Barré syndrome in adults. Because no licensed vaccine or specific antiviral treatment is available for ZIKV infection, the most commonly used approach to control the spread of ZIKV is suppression of the mosquito vector population. A novel proposed strategy to block arthropod virus (arbovirus) transmission is based on the chemical inhibition of virus infection in mosquitoes. However, only a few drugs and compounds have been tested with such properties. Here we present a comprehensive screen of 55 FDA-approved anti-flaviviral drugs for potential anti-ZIKV and mosquitocidal activity. Four drugs (auranofin, actinomycin D (Act-D), bortezomib and gemcitabine) were toxic to C6/36 cells, and two drugs (5-fluorouracil and mycophenolic acid (MPA)) significantly reduced ZIKV production in C6/36 cells at 2 μM and 0.5 μM, respectively. Three drugs (Act-D, cyclosporin A, ivermectin) exhibited a strong adulticidal activity, and six drugs (U18666A, retinoic acid p-hydroxyanilide (4-HPR), clotrimazole, bortezomib, MPA, imatinib mesylate) significantly suppressed ZIKV infection in mosquito midguts. Some of these FDA-approved drugs may have potential for use for the development of ZIKV transmission-blocking strategies.https://doi.org/10.1371/journal.pntd.0007681
spellingShingle Shengzhang Dong
Seokyoung Kang
George Dimopoulos
Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti.
PLoS Neglected Tropical Diseases
title Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti.
title_full Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti.
title_fullStr Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti.
title_full_unstemmed Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti.
title_short Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti.
title_sort identification of anti flaviviral drugs with mosquitocidal and anti zika virus activity in aedes aegypti
url https://doi.org/10.1371/journal.pntd.0007681
work_keys_str_mv AT shengzhangdong identificationofantiflaviviraldrugswithmosquitocidalandantizikavirusactivityinaedesaegypti
AT seokyoungkang identificationofantiflaviviraldrugswithmosquitocidalandantizikavirusactivityinaedesaegypti
AT georgedimopoulos identificationofantiflaviviraldrugswithmosquitocidalandantizikavirusactivityinaedesaegypti